Search

Introduction: Global predictions indicate that the incidence of retinopathy of prematurity (ROP) is increasing, but the lack of current epidemiological data on the occurrence of ROP in Europe prompted the authors to update these data. Methods: European studies related to the presence of ROP were analyzed, and the reason for the differences in the percentage of ROP and different screening criteria were checked. Results: The study presents results from individual and multiple centers. Current ROP incidence data varies from a low of 9.3% in Switzerland to the highest values of 64.1% in Portugal and 39.5% in Norway. The national screening criteria are used in the Netherlands, Germany, Norway, Poland, Portugal, Switzerland, and Sweden. Uniform criteria—Royal College of Paediatrics and Child Health guidelines are used in England and Greece. American Academy of Pediatrics screening guidelines are used in France and Italy. Conclusions: The epidemiology of ROP in European countries varies significantly. The increase in the diagnosis and treatment rate of ROP in recent years correlates with the narrowing of diagnostic criteria in newly issued guidelines (which include the WINROP and G-ROP algorithms), a higher number of less developed preterm infants, and a lower percentage of live births. [ABSTRACT FROM AUTHOR]

Introduction: The authors present the prevalence of refractive errors in premature infants, demonstrating the relationship between refractive development and selected demographic characteristics and the forms of treatment used: diode laser, anti-vascular endothelial growth factor (anti-VEGF) and combination therapy. Material and methods: The study included 56 healthy children without retinopathy of prematurity (ROP) and 63 children with ROP. Ophthalmologic evaluation and diagnosis were performed according to the International Classification of Retinopathy of Prematurity assessed in Ret-Cam 3. Treatment of ROP was carried out according to the guidelines of the Polish Ophthalmological Society using a diode laser (IRIDEX IQ 810) and an anti-VEGF intravitreal preparation (ranibizumab, Lucentis) at a reduced dose of 0.18 mg. Refractive measurements were taken at 7 months of age using a handheld computerized autorefractometer (Retinomax) after 1% tropicamide cycloplegia. Results: A statistically significantly higher prevalence of high myopia (p = 0.019) and low astigmatism (p < 0.001) was observed in the eyes of premature infants with ROP and moderate hyperopia in the group without ROP (p = 0.031) regardless of the treatment used [mean +1.33 spherical diopters (Dsfr.); SD ±3.09 for eyes with ROP vs. mean +2.42 Dsfr.; SD ±2.11 for eyes without ROP]. Birth weight (p = 0.01) and gestational age (p = 0.048) correlated with changes in spherical refraction in children with ROP. There were statistically significant differences in high myopia (p = 0.041), low myopia (p = 0.010) and low hyperopia (p = 0.014) in the group of premature infants treated for ROP depending on the form of therapy. Conclusions: There were statistically significant differences in high myopia (p = 0.041), low myopia (p = 0.010) and low hyperopia (p = 0.014) in the groups of premature infants with ROP and high myopia (p = 0.019) and low astigmatism (p < 0.001) in the groups treated with monotherapy or combined therapy. Birth weight (p = 0.01) and gestational age (p = 0.048) had a significant effect on refractive development in eyes with ROP. [ABSTRACT FROM AUTHOR]